If you might recall, even when the full data was — well, patients were enrolled back in November 2021. From then, we projected that this will be beyond year end 2022. If you recall at that time, although, many people were telling us, these are relapsed/refractory AML patients, typically they would live around six, seven months, so we should get data before that. But that wasn’t what we were seeing from the beginning, from the get go. So we’re very pleased with the way we’ve been projecting. And of course, as data matures, as events mature, as the event curve is something we look carefully at, we continue to update our projections and we communicated those projections to the market whenever there was a difference between what was previously communicated.
So at the interim analysis, Roger, one of the things that has happened as well is our clinical operations team really did a good job in the data cleaning. As you can imagine, preparing for an interim analysis, we would have been ready to go should that threshold have been passed. So where we have a very robust database now. And based on that database robustness, we also updated our projections and now what we’re saying is going to be within H1 2024. So we think the fact that patients continue to live longer is a good thing. We don’t exactly know is it uproleselan, is it standard of care, is it a combination? Obviously, we’re blinded, and we continue to be blinded to the data. But from what we see of this longer median follow-up from what we see in our pooled blinded data, we continue to remain very encouraged by the potential uproleselan has to relapsed/refractory AML patients and hopefully beyond that as well as the NCI data and other ISTs mature.
Does that answer your question, Roger?
Roger Song: Maybe just a follow up question. Understanding you are focusing on upro for the Phase II, Phase III R/R AML trial. And since you have some time about a year before you will have the top line data, what are the key backlog activity you have been — you and the team have been preparing for the data and the potential registration commercial?
Harout Semerjian: I mean, one of the things which — now that the interim analysis, which was very important for us to do for ethical considerations is behind us and we have an updated look at when the full events would potentially happen. We continue to leverage this time to also engage with the medical community. As you know, uproleselan has a very unique mechanism of action, it’s novel, it’s complementary in terms of tackling an extrinsic chemo resistance pathway that can potentially complement other pathways in diseases that are as heterogeneous as AML. So we continue to really engage with the medical community through both Ed’s team and Bruce’s team to really make sure that uproleselan and E-selectin antagonism as a mechanism is really in the limelight of the medical expert community. So that’s one of the things that we continue to do and this timing actually allows us a bit more ability to do some of that in a very smart, cost effective manner.
Operator: Thank you. There are no more questions in the queue. I’d like to turn the call back to Mr. Semerjian for closing remarks.
Harout Semerjian: Thank you, operator. And thank you for everyone for joining our call today. We look forward to keeping you up-to-date on GlycoMimetics. Have a great day.
Operator: This concludes today’s call. You may now disconnect. Everyone, have a great day.
